Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2024, BioMarin Pharmaceutical (BMRN) reported revenue of $747.31 million, up 15.7$0.92, compared to $0.49 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of$711.93 million, representing a surprise of +4.97%. The company delivered an EPS surprise of +26.03%, with the consensus EPS estimate being $0.73.While investors closely watch year-over-year changes in headline numbers -- revenue and ear ...